Issue: October 2019

Read more

October 10, 2019
1 min read
Save

Low-dose radiography protocol was accurate for use with idiopathic scoliosis curves

Issue: October 2019
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

CHICAGO — Cobb angle measurement and radiographic follow-up after curve correction could be reliably performed in patients with early onset idiopathic scoliosis using a low-dose radiographic system, according to results of a prospective data collection study presented at the North American Spine Society Annual Meeting, here.

Tristan Langlais, MD, MSc, of Paris, and his colleagues studied the efficacy and safety of a freestanding, biplanar, low-dose stereoradiography system and hypothesized its use could be a minimally invasive method to evaluate children younger than 6 years of age with early onset idiopathic scoliosis (EOIS).

The researchers evaluated intraoperator and interoperator reliability of this 2-D technique when it was used by three observers to measure Cobb angles for 41 patients with EOIS and a mean age of 4 years. The mean Cobb angle was 22°, which ranged from 10° to 80°.

The Cobb angles were measured two different times by the observers using the pedicle line method, Langlais noted.

“The dose of radiation was two-times less than digital X-ray,” he said.

Concerning the results, “the reliability of the study was good, regardless of the Cobb angle and age of children,” Langlais said.

“Cobb angle measurement on low-dose stereoradiography is feasible and reliable in idiopathic scoliotic curve before 6 years old using the pedicle line, despite the bone immaturity,” he said. – by Susan M. Rapp

Reference:

Pietton R, et al. Abstract 203. Presented at: North American Spine Society Annual Meeting; Sept. 25-28, 2019; Chicago.

Disclosure: Langlais reports no relevant financial disclosures.